$SLDB
Solid Biosciences Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023042371 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.410M $7.129M
YoY Change -10.06% 4.06%
% of Gross Profit
Research & Development $16.70M $19.78M
YoY Change 19.26% -14.68%
% of Gross Profit
Depreciation & Amortization $588.0K $703.0K
YoY Change 34.25% -2.63%
% of Gross Profit
Operating Expenses $23.11M $26.84M
YoY Change 9.38% -14.92%
Operating Profit -$23.11M -$26.84M
YoY Change 9.38% 5.76%
Interest Expense $1.860M $1.949M
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.134M $2.214M
YoY Change 195.57% 663.45%
Pretax Income -$20.98M -$24.63M
YoY Change 2.79% -1.85%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.98M -$24.63M
YoY Change 2.79% -1.85%
Net Earnings / Revenue
Basic Earnings Per Share -$1.05 -$1.25
Diluted Earnings Per Share -$1.05 -$1.25
COMMON SHARES
Basic Shares Outstanding 20.06M 19.60M
Diluted Shares Outstanding 20.06M 19.66M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $142.9M $160.2M
YoY Change 0.51% -1.65%
Cash & Equivalents $49.04M $91.57M
Short-Term Investments $93.85M $68.62M
Other Short-Term Assets $5.500M $7.283M
YoY Change 2.77% -3.61%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $148.3M $167.5M
YoY Change 0.57% -1.74%
LONG-TERM ASSETS
Property, Plant & Equipment $7.045M $7.391M
YoY Change 12.43% 7.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $315.0K $181.0K
YoY Change -25.36% -58.68%
Total Long-Term Assets $36.38M $37.25M
YoY Change -1.58% -2.13%
TOTAL ASSETS
Total Short-Term Assets $148.3M $167.5M
Total Long-Term Assets $36.38M $37.25M
Total Assets $184.7M $204.7M
YoY Change 0.14% -1.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.898M $2.968M
YoY Change -63.15% -41.91%
Accrued Expenses $11.47M $10.51M
YoY Change 11.59% -34.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $400.0K $419.0K
YoY Change 13.31% 1.7%
Total Short-Term Liabilities $15.82M $15.87M
YoY Change -6.55% -26.95%
LONG-TERM LIABILITIES
Long-Term Debt $1.400M $1.482M
YoY Change
Other Long-Term Liabilities $23.20M $23.65M
YoY Change -4.42% -3.66%
Total Long-Term Liabilities $24.60M $25.13M
YoY Change 1.34% 2.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.82M $15.87M
Total Long-Term Liabilities $24.60M $25.13M
Total Liabilities $40.37M $40.99M
YoY Change -2.02% -11.39%
SHAREHOLDERS EQUITY
Retained Earnings -$638.4M -$617.4M
YoY Change 16.59% 17.12%
Common Stock $782.8M $781.2M
YoY Change 13.27% 13.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $144.4M $163.7M
YoY Change
Total Liabilities & Shareholders Equity $184.7M $204.7M
YoY Change 0.14% -1.81%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$20.98M -$24.63M
YoY Change 2.79% -1.85%
Depreciation, Depletion And Amortization $588.0K $703.0K
YoY Change 34.25% -2.63%
Cash From Operating Activities -$17.90M -$27.47M
YoY Change -12.38% 72.98%
INVESTING ACTIVITIES
Capital Expenditures $390.0K $536.0K
YoY Change -146.48% -147.18%
Acquisitions
YoY Change
Other Investing Activities -$24.25M -$47.70M
YoY Change -253.99% -18.41%
Cash From Investing Activities -$24.64M -$48.23M
YoY Change -265.27% -19.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 2.617M
YoY Change -100.0% 3484.93%
NET CHANGE
Cash From Operating Activities -17.90M -27.47M
Cash From Investing Activities -24.64M -48.23M
Cash From Financing Activities 0.000 2.617M
Net Change In Cash -42.54M -73.08M
YoY Change 670.51% -3.08%
FREE CASH FLOW
Cash From Operating Activities -$17.90M -$27.47M
Capital Expenditures $390.0K $536.0K
Free Cash Flow -$18.29M -$28.00M
YoY Change -6.64% 89.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001707502
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2
0
CY2022 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2
0
sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2
0
CY2022 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2
0
sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1
0
CY2022 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1
0
sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1
0
CY2022 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38360
dei Entity Registrant Name
EntityRegistrantName
Solid Biosciences Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0943402
dei Entity Address Address Line1
EntityAddressAddressLine1
500 Rutherford Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Third FloorCharlestown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02129
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
337-4680
dei Security12b Title
Security12bTitle
Common Stock $0.001 par value per share
dei Trading Symbol
TradingSymbol
SLDB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20060039
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91569000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155384000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
68623000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
58338000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7283000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5916000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
167475000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
219638000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27841000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28949000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7391000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9657000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
181000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
175000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2023Q2 us-gaap Assets
Assets
204721000
CY2022Q4 us-gaap Assets
Assets
260252000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2968000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3238000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10509000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16691000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1853000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1897000
CY2023Q2 sldb Finance Liabilities And Finance Lease Sale And Lease Back Liabilities Current
FinanceLiabilitiesAndFinanceLeaseSaleAndLeaseBackLiabilitiesCurrent
419000
CY2022Q4 sldb Finance Liabilities And Finance Lease Sale And Lease Back Liabilities Current
FinanceLiabilitiesAndFinanceLeaseSaleAndLeaseBackLiabilitiesCurrent
668000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
117000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15866000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22508000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23645000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24279000
CY2023Q2 sldb Finance Liabilities And Finance Lease Sale And Lease Back Liabilities Noncurrent
FinanceLiabilitiesAndFinanceLeaseSaleAndLeaseBackLiabilitiesNoncurrent
1482000
CY2022Q4 sldb Finance Liabilities And Finance Lease Sale And Lease Back Liabilities Noncurrent
FinanceLiabilitiesAndFinanceLeaseSaleAndLeaseBackLiabilitiesNoncurrent
1703000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
96000
CY2023Q2 us-gaap Liabilities
Liabilities
40993000
CY2022Q4 us-gaap Liabilities
Liabilities
48586000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20044389
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20044389
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19556732
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19556732
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
20000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
781131000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
774452000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-68000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-617437000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-562738000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
163728000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
211666000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204721000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
260252000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19777000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23180000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44408000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43125000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7129000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6851000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14528000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14203000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
-63000
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
1520000
us-gaap Restructuring Charges
RestructuringCharges
-63000
us-gaap Restructuring Charges
RestructuringCharges
1520000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
26843000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
31551000
us-gaap Operating Expenses
OperatingExpenses
58873000
us-gaap Operating Expenses
OperatingExpenses
58848000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26843000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-25382000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58873000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50754000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1949000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
293000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3627000
us-gaap Investment Income Interest
InvestmentIncomeInterest
347000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
265000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
547000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2214000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
290000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4174000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
334000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-24629000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-25092000
us-gaap Profit Loss
ProfitLoss
-54699000
us-gaap Profit Loss
ProfitLoss
-50420000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.33
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.71
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19663672
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19663672
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7523964
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7523964
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19618517
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19618517
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7515673
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7515673
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-24629000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-25092000
us-gaap Profit Loss
ProfitLoss
-54699000
us-gaap Profit Loss
ProfitLoss
-50420000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-71000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
82000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-77000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-24620000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-25163000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-54617000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-50497000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
183787000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1944000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
65000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2539000
CY2023Q2 sldb Issuance Of Common Stock Value To Related Party In Connection With Stock Purchase Agreement
IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement
78000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-24629000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
163728000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
211666000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4062000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
65000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2539000
sldb Issuance Of Common Stock Value To Related Party In Connection With Stock Purchase Agreement
IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement
78000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
82000
us-gaap Profit Loss
ProfitLoss
-54699000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
163728000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
185511000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1814000
CY2022Q2 sldb Issuance Of Common Stock Value To Related Party In Connection With Stock Purchase Agreement
IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement
73000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-71000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-25092000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
162235000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
208211000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4426000
sldb Pre Funded Warrants Exercise During Period Value
PreFundedWarrantsExerciseDuringPeriodValue
22000
sldb Issuance Of Common Stock Value To Related Party In Connection With Stock Purchase Agreement
IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement
73000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-77000
us-gaap Profit Loss
ProfitLoss
-50420000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
162235000
us-gaap Profit Loss
ProfitLoss
-54699000
us-gaap Profit Loss
ProfitLoss
-50420000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
273000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-526000
us-gaap Share Based Compensation
ShareBasedCompensation
4062000
us-gaap Share Based Compensation
ShareBasedCompensation
4426000
sldb Depreciation And Impairment Expense
DepreciationAndImpairmentExpense
1780000
sldb Depreciation And Impairment Expense
DepreciationAndImpairmentExpense
1431000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
249000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-962000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-586000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-110000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
373000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-7323000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8229000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8080000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55460000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43068000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1042000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1320000
us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-58632000
us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-92156000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
68562000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
112688000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10972000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21852000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2539000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
22000
sldb Employee Stock Purchases And Withholdings
EmployeeStockPurchasesAndWithholdings
78000
sldb Employee Stock Purchases And Withholdings
EmployeeStockPurchasesAndWithholdings
73000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2617000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-63815000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-64825000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
157217000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121206000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93402000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56381000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
417000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
29126000
sldb Increase Decrease In Right Of Use Asset Due To Lease Termination
IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination
-252000
sldb Increase Decrease In Right Of Use Asset Due To Lease Termination
IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination
-464000
sldb Increase Decrease In Property Plant And Equipment Due To Asset Exchange
IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange
-950000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
141000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
600000
CY2022Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-15
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.015
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-617437000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-24629000
us-gaap Profit Loss
ProfitLoss
-54699000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55460000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
160192000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
1833000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, the recognition of research and development expenses and equity-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has made estimates of the impact of the recent COVID-19 pandemic within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates.</span></p>
CY2023Q2 us-gaap Deposit Assets
DepositAssets
1833000
CY2022Q4 us-gaap Deposit Assets
DepositAssets
1833000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91569000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155384000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54311000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
119136000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
237000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2070000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93402000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
157217000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56381000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121206000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
68609000
sldb Proceeds From Sale And Lease Back Transactions
ProceedsFromSaleAndLeaseBackTransactions
2143000
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
65134000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
68623000
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
133757000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
69374000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
58338000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
127712000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
68609000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
68623000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
58406000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
68000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
58338000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
68609000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
68623000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
68623000
sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y4M24D
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
58406000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
58338000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
58406000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
58338000
CY2022 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y6M
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18951000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20613000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11560000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10956000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7391000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9657000
CY2023Q2 us-gaap Depreciation
Depreciation
703000
us-gaap Depreciation
Depreciation
1406000
CY2022Q2 us-gaap Depreciation
Depreciation
722000
us-gaap Depreciation
Depreciation
1431000
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
374000
CY2022Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q2 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
4385000
CY2022Q4 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2913000
CY2023Q2 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
2898000
CY2022Q4 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
3003000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7283000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5916000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10509000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16691000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
127167
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
301905
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1944000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1814000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4062000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4426000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24629000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25092000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54699000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50420000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19618517
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19618517
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7515673
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7515673
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.33
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.71
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3193408
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1946525

Files In Submission

Name View Source Status
0000950170-23-042371-index-headers.html Edgar Link pending
0000950170-23-042371-index.html Edgar Link pending
0000950170-23-042371.txt Edgar Link pending
0000950170-23-042371-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sldb-20230630.htm Edgar Link pending
sldb-20230630.xsd Edgar Link pending
sldb-ex10_1.htm Edgar Link pending
sldb-ex10_2.htm Edgar Link pending
sldb-ex31_1.htm Edgar Link pending
sldb-ex31_2.htm Edgar Link pending
sldb-ex32_1.htm Edgar Link pending
sldb-ex32_2.htm Edgar Link pending
sldb-20230630_cal.xml Edgar Link unprocessable
sldb-20230630_def.xml Edgar Link unprocessable
sldb-20230630_lab.xml Edgar Link unprocessable
sldb-20230630_pre.xml Edgar Link unprocessable
sldb-20230630_htm.xml Edgar Link completed